Increasing Adoption of Blood-Based Cancer Tests Enhancing Market Value
The global multi-cancer early detection (MCED) market is gaining remarkable momentum as healthcare systems shift toward proactive and population-wide cancer monitoring. Multi-cancer early detection technologies—powered by liquid biopsies, genomics, AI-driven biomarkers and blood-based screening—are redefining how cancers are identified long before symptoms appear. With...
0 Комментарии 0 Поделились 6 Просмотры 0 предпросмотр